Abstract
STUDY OBJECTIVES: The validity of consumer-targeted wrist-worn sleep measurement systems has been little studied in children and adolescents. We examined the validity of a new fitness tracker (PFT) manufactured by Polar Electro Oy and the previously validated Actiwatch 2 (AW2) from Philips Respironics against polysomnography (PSG) in children and adolescents. METHODS: Seventeen children (age 11.0 ± 0.8 years) and 17 adolescents (age 17.8 ± 1.8 years) wore the PFT and AW2 concurrently with an ambulatory PSG in their own home for 1 night. We compared sleep onset, offset, sleep interval (time from sleep on to offset), actual sleep time (time scored as sleep between sleep on and offset), and wake after sleep onset (WASO) between accelerometers and PSG. Sensitivity, specificity, and accuracy were calculated from the epoch-by-epoch data. RESULTS: Both devices performed adequately against PSG, with excellent sensitivity for both age groups (> 0.91). In terms of specificity, the PFT was adequate in both groups (> 0.77), and AW2 adequate in children (0.68) and poor in adolescents (0.58). In the younger group, the PFT underestimated actual sleep time by 29.9 minutes and AW2 underestimated actual sleep time by 43.6 minutes. Both overestimated WASO, PFT by 24.4 minutes and AW2 by 20.9 minutes. In the older group, both devices underestimated actual sleep time (PFT by 20.6 minutes and AW2 by 26.8 minutes) and overestimated WASO (PFT by 12.5 minutes and AW2 by 14.3 minutes). Both devices were accurate in defining sleep onset. CONCLUSIONS: This study suggests that this consumer-targeted wrist-worn device performs as well as, or even better than, the previously validated AW2 against PSG in children and adolescents. Both devices underestimated sleep but to a lesser extent than seen in many previous validation studies on research-targeted accelerometers.